




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/08, 9/19, 47/02, 47/12, 47/26, 38/29</b>		<b>A3</b>	(11) International Publication Number: <b>WO 99/55353</b>
			(43) International Publication Date: 4 November 1999 (04.11.99)
(21) International Application Number: PCT/CA99/00376			(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 26 April 1999 (26.04.99)			
(30) Priority Data: 9801495-4 28 April 1998 (28.04.98) SE			
(71) Applicant (for all designated States except US): ALLELIX BIOPHARMACEUTICALS INC. [CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1VY (CA).			
(72) Inventors; and (75) Inventors/Applicants (for US only): <u>BILLGER</u> , Martin [SE/SE]; Astra Hassle AB, S-431 83 Molndal (SE). <u>BRULLS</u> , Mikael [SE/SE]; Astra Hassle AB, S-431 83 Molndal (SE).			
(74) Agent: HIRONS, Robert, G.; 150 Metcalfe Street, Ottawa, Ontario K2P 1P1 (CA).			Published With international search report.
			(88) Date of publication of the international search report: 13 January 2000 (13.01.00)

(54) Title: PROTEIN FORMULATIONS



## (57) Abstract

The present invention relates to pharmaceutical formulations comprising human parathyroid hormone at a concentration from 0.3 to 10 mg/ml, a pharmaceutically acceptable buffer having a pH from 4 to 6, and at least one tonicity modifier. The said pharmaceutical formulations are useful for the treatment of bone related disorders such as osteoporosis.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup> :

A61K 38/00

A2

(11) International Publication Number:

WO 99/55353

(43) International Publication Date: 4 November 1999 (04.11.99)

(21) International Application Number: PCT/CA99/00376

(22) International Filing Date: 26 April 1999 (26.04.99)

(30) Priority Data:

9801495-4

28 April 1998 (28.04.98)

SE

(71) Applicant (for all designated States except US): ALLELIX  
BIOPHARMACEUTICALS INC. [CA/CA]; 6850 Goreway  
Drive, Mississauga, Ontario L4V 1VY (CA).

(72) Inventors; and


(75) Inventors/Applicants (for US only): BILLGER, Martin  
[SE/SE]; Astra Hassle AB, S-431 83 Molndal (SE).  
BRULLS, Mikael [SE/SE]; Astra Hassle AB, S-431 83  
Molndal (SE).(74) Agent: HIRONS, Robert, G.; 150 Metcalfe Street, Ottawa,  
Ontario K2P 1P1 (CA).(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG,  
BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB,  
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,  
SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA,  
ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ,  
UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI  
patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR,  
NE, SN, TD, TG).

## Published

Without international search report and to be republished  
upon receipt of that report.

(54) Title: PROTEIN FORMULATIONS

PTH degradation rate Vs PTH concentration



## (57) Abstract

The present invention relates to pharmaceutical formulations comprising human parathyroid hormone at a concentration from 0.3 to 10 mg/ml, a pharmaceutically acceptable buffer having a pH from 4 to 6, and at least one tonicity modifier. The said pharmaceutical formulations are useful for the treatment of bone related disorders such as osteoporosis.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		